by OTMS Staff | Feb 25, 2026 | PatentVest Pulse
Author: Tyler Teske Wegovy and Zepbound (semaglutide, tirzepatide) built a $71 billion market by treating less than 5% of eligible patients. The other 95% remain untreated, not because the drugs don’t work, but because needles, cold chains, and $1,000-per-month...
by OTMS Staff | Feb 5, 2026 | Uncategorized
Author: Sarah Cork, Ph.D. Early-stage biotech companies generally understand that intellectual property management, in particular, patenting their crown-jewel technology, is a critical component of sound business strategy. But how might investment in the...
Recent Comments